J&J mops up $900M in waste, writ­ing off the last big chunk of the $1.75B it spent to ac­quire Alios

Back in the fall of 2014, Alios looked like quite a find for J&J, with its lead RSV drug and some ear­ly stage hep C pro­grams as a group of ri­vals fought over the block­buster mar­ket that await­ed the win­ner of that con­test.

Now, more than 4 years af­ter J&J plunked down $1.75 bil­lion in cash to ac­quire lit­tle Alios, J&J is fold­ing its hand and walk­ing away from what proved a bad bet. Af­ter writ­ing off $630 mil­lion for AL-8176 last year, the phar­ma gi­ant has come back to to elim­i­nate the re­main­ing $900 mil­lion, with noth­ing to show for it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.